Sep. 8 at 1:26 PM
$BWAY BrainsWay closed a record-breaking quarter (Q2), reflecting strong demand for our noninvasive neurostimulation tech & commitment to advancing mental health care.
Key Highlights:
• Revenue:
$12.6M, up 26% YoY
• EBITDA: +40% YoY in H1 2025
• Net Profit:
$2M, up 240% YoY
• Performance Obligations:
$62M, up 25% YoY
• Cash Flow: 8 consecutive quarters of positive free cash flow
• Guidance: Raised full-year 2025 Revenue and EBITDA outlook
Operational Momentum:
• 88 systems shipped in Q2 (+35% YoY); global installed base reached 1,522 systems
• ~70% of recent customer engagements structured as multi-year lease agreements
Strategic Partnerships:
• Completed equity financings with Stella MSO and Axis MSO, two leading clinic networks
Innovation Pipeline:
• FDA submissions for accelerated MDD & adolescent depression protocols
• PTSD expansion through collaboration with the Israel Ministry of Defense to support soldiers
• BrainsWay continues to expand access, drive innovation, & lead in Deep TMS tech